Mesenchymal Stem Cells Market Size, Share & Trends Analysis Report By Product & Services, By Workflow Type, By Type, By Source Of Isolation, By Indication, By Application, By Region, And Segment Forecasts, 2024 - 2030

Mesenchymal Stem Cells Market Size, Share & Trends Analysis Report By Product & Services, By Workflow Type, By Type, By Source Of Isolation, By Indication, By Application, By Region, And Segment Forecasts, 2024 - 2030

Mesenchymal Stem Cells Market Growth & Trends

The global mesenchymal stem cells (MSC) market size is expected to reach USD 7.27 billion by 2030, expanding at a CAGR of 12.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. An exponential increase in Mesenchymal Stem Cell (MSC) based research and its implications in the field of regenerative medicine is anticipated to fuel the industry expansion. Moreover, the constantly evolving landscape of cell therapies is also anticipated to propel investments in the mesenchymal stem cells market space; large-scale operational firms are targeting small or emerging players with an operating strategy of acquisition to bolster their market presence.

The strong pipeline of mesenchymal stem cell-based products coupled with emerging applications of mesenchymal stem cells is anticipated to accelerate the industry growth. For instance, in 2022, the U.S.FDA has approved around 19 stem cell therapies for range of life-threatening disorders. Some of these therapies include, BREYANZI of BMS, ALLOCORD, KYMIRAH of Novartis etc. Moreover, a substantial number of companies are exploring the potential of MSCs as therapeutic regime for the management of inflammatory conditions, in turn, boosting market growth.

For instance, on January 2022, the Century Therapeutics and Bristol Myers Squibb entered a collaboration to expand IPSC-derives allogenic cell therapies. In addition, Takeda/TiGenix phase 3 clinical trial incorporated mesenchymal stem cells for complex perianal fistulas in Crohn's Disease. This was the most successful late-stage clinical trial as of September 2020. In addition, in August 2022 AGC Biologics partnered with human mesenchymal stem cell supplier, RoosterBio Inc. to deliver clinically proven advanced therapies for life-threatening conditions. These factors are projected to bolster the usage of stem cell products offered by key entities, thereby intensifying the market competition.

Market players are focused on the expansion of their offerings through extensive R&D and the formation of alliances and partnerships with other major players to sustain their market position. Owing to the recent pandemic of COVID-19, several research and academic research institutes are making focused efforts to develop a treatment regime by using mesenchymal stem cells.

Mesenchymal Stem Cells Market Report Highlights

• The products segment dominated the segment and accounted for the largest revenue share of 78.89% in 2023. Among the products, the cells and cell lines segment has emerged as a key contributor to the segment’s revenue
• Based on workflow type, the culture and cryopreservation segment dominated the industry with revenue share of 44.55% in 2023. The segment growth is attributed to the high demand for cryopreservation services and enhancement of healthcare infrastructure in developing economies
• The allogenic MSCs segment accounted for the higher revenue share of 56.60% in 2023. This is attributed to the high safety profile of allogeneic mesenchymal stem cells in clinical applications
• The bone marrow segment dominated the market and accounted for the largest revenue share of 24.56% in 2023. Bone marrow is a major source of isolation for mesenchymal cells
• The disease modelling application segment dominated the application and accounted for the largest revenue share of 35.23% in 2023. The use of cellular disease models with patient specific MSCs provides an ideal tool for pathological research
• North America dominated the market and accounted for the largest revenue share of 45.11% in 2023. The higher revenue share of the region is accounted to supportive government legislation and rising application of cell therapies in chronic disorders

Please note The report will be delivered in 2-3 business days upon order notification. Show more